Ophthalmic Business News

Health Canada approved the enVista Envy full visual range IOL, the first global approval for the lens, according to a press release from Bausch + Lomb.

Ophthalmology practices increasingly face a choice in how their marketing operations are run: Embrace AI-enabled systems and stay competitive, or maintain traditional but proven promotional strategies and possibly be left behind.

The FDA approved Yesafili and Opuviz as the first interchangeable biosimilars to Eylea, according to a press release from the FDA.

The FDA granted de novo marketing authorization to Notal Vision for the patient self-operated AI-powered Scanly Home OCT device, according to a press release.

A physician practice owner’s week is spent seeing and caring for patients and managing the day-to-day issues of the practice.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Riad Sherif, MD, CEO of Oculis, discusses the company’s two phase 3 clinical trials for the OCS-01 eye drop.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Jay S. Duker, MD, of EyePoint Pharmaceuticals discusses lead product Duravyu.

In this episode, Dagny Zhu, MD, Cathleen McCabe, MD, and Susan MacDonald, MD, chat with Jeannette Bankes about leadership in eye care and mentoring the next generation of leaders.

Qlaris Bio raised $24 million during series B financing for the clinical development of QLS-111, a new IOP-lowering drug candidate for patients with glaucoma, the company announced in a press release.

The FDA accepted an investigational new drug application for a trispecific fusion antibody for the treatment of diabetic macular edema, according to a press release from Eluminex Biosciences.